Well MDV3100 in early stage trials (at a higher dose) had a couple of seizures reported as SAEs. Even a low seizure incidence might seriously hamper its commercial prospects compared with Zytiga - not saying it should do so given the know long-term adverse effects of steroids, but I think it would.
Note the steroid dose for Zytiga is pretty small, but I think it is enough to make doctors think twice if they have a comparable steroid-free alternative.
If it is just comparable to Zytiga plus prednisone, I don't think MDV3100 automatically becomes SOC. If you base on topline efficacy data alone, it's too early to say. I had discussion previously the large number difference between placebo arms could imply there are differences in enrolled patient population to explain the mOS difference.
Market Data 
Markets 
AI
